Related Experiment Video

Updated: Aug 17, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives

Eugene A Woltering1

  • 1Louisiana State University Health Sciences Center, Department of Surgery, LSUHSC Stanley S. Scott Cancer Center, LSUHSC Neuroscience Center of Excellence, and The Veterans Affairs Medical Center, New Orleans, Louisiana 70112, USA. ewolte@lsuhsc.edu

Cancer Biotherapy & Radiopharmaceuticals
|September 25, 2003
PubMed

Insights

Somatostatin analogs inhibit angiogenesis, the formation of new blood vessels crucial for tumor growth. This targeted approach shows promise, particularly due to the overexpression of somatostatin receptor subtype 2 (sst 2) on proliferating endothelial cells.

Area of Science:

  • Oncology
  • Vascular Biology
  • Pharmacology

Background:

  • Angiogenesis is vital for tumor growth and metastasis.
  • Current anti-angiogenic therapies lack targeted approaches.
  • Somatostatin analogs show potential as targeted anti-angiogenic agents.

Purpose of the Study:

  • To review the development of somatostatin analogs as anti-angiogenic agents.
  • To explore their potential in combination with other anti-cancer compounds.
  • To highlight the role of somatostatin receptor subtype 2 (sst 2) in this process.

Main Methods:

  • Demonstration of somatostatin analog inhibition in various angiogenesis models (CAM, HUVEC, HPVAM).
  • Investigation of somatostatin receptor subtype 2 (sst 2) expression during endothelial cell proliferation.
  • Review of unlabeled and radiolabeled somatostatin analogs.

Main Results:

  • Somatostatin analogs effectively inhibit angiogenesis in preclinical models.
  • Inhibition correlates with the upregulation of somatostatin receptor subtype 2 (sst 2) on proliferating endothelial cells.
  • Overexpression of sst 2 provides a specific target for somatostatin analog therapies.

Conclusions:

  • Somatostatin analogs are promising targeted anti-angiogenic agents.
  • The specific targeting of sst 2 offers a novel therapeutic strategy.
  • Future developments may involve somatostatin analog conjugates for enhanced efficacy.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.